Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403086 · ClinicalTrials.gov registry record · Phase 2
Pragmatic Trial of Psilocybin Therapy in Palliative Care
A Phase 2 study of Demoralization, sponsored by Charles S. Grob, M.D..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT05403086 is a Phase 2 study of Demoralization that is actively recruiting participants, run by Charles S. Grob, M.D.. The registered enrollment target is 100 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT05403086, a Phase 2 study of Demoralization, is actively recruiting participants, sponsored by Charles S. Grob, M.D..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Psilocybin
Study Locations (5)
California
- Marin Cancer Care - Greenbrae
- University of California, Los Angeles - Los Angeles
- University of San Francisco - San Francisco
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Maryland
- Sunstone Therapies - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-01-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403086
The ClinicalTrials.gov registry entry for NCT05403086 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles S. Grob, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Demoralization appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT05403086 reports 5 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05403086 about?
NCT05403086 is a clinical study titled "Pragmatic Trial of Psilocybin Therapy in Palliative Care". This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
What is the current status of trial NCT05403086?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-01-19. Estimated completion is 2027-12-31.
What conditions does trial NCT05403086 study?
This clinical trial studies the following conditions: Demoralization.
What interventions are being tested in trial NCT05403086?
The interventions under investigation include: Ketamine (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05403086?
This trial is sponsored by Charles S. Grob, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403086 being conducted?
This trial has 5 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Demoralization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.